These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33218364)

  • 1. Pre-depletion of TRBC1+ T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies.
    Zhang C; Palashati H; Rong Z; Lin N; Shen L; Liu Y; Li S; Yu B; Yang W; Lu Z
    Mol Cancer; 2020 Nov; 19(1):162. PubMed ID: 33218364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers.
    Nichakawade TD; Ge J; Mog BJ; Lee BS; Pearlman AH; Hwang MS; DiNapoli SR; Wyhs N; Marcou N; Glavaris S; Konig MF; Gabelli SB; Watson E; Sterling C; Wagner-Johnston N; Rozati S; Swinnen L; Fuchs E; Pardoll DM; Gabrielson K; Papadopoulos N; Bettegowda C; Kinzler KW; Zhou S; Sur S; Vogelstein B; Paul S
    Nature; 2024 Apr; 628(8007):416-423. PubMed ID: 38538786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering genetic devices for in vivo control of therapeutic T cell activity triggered by the dietary molecule resveratrol.
    Yang L; Yin J; Wu J; Qiao L; Zhao EM; Cai F; Ye H
    Proc Natl Acad Sci U S A; 2021 Aug; 118(34):. PubMed ID: 34404729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies.
    Maciocia PM; Wawrzyniecka PA; Philip B; Ricciardelli I; Akarca AU; Onuoha SC; Legut M; Cole DK; Sewell AK; Gritti G; Somja J; Piris MA; Peggs KS; Linch DC; Marafioti T; Pule MA
    Nat Med; 2017 Dec; 23(12):1416-1423. PubMed ID: 29131157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
    Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
    Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
    Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
    Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
    Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
    Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
    Cooper ML; Choi J; Staser K; Ritchey JK; Devenport JM; Eckardt K; Rettig MP; Wang B; Eissenberg LG; Ghobadi A; Gehrs LN; Prior JL; Achilefu S; Miller CA; Fronick CC; O'Neal J; Gao F; Weinstock DM; Gutierrez A; Fulton RS; DiPersio JF
    Leukemia; 2018 Sep; 32(9):1970-1983. PubMed ID: 29483708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function.
    Salzer B; Schueller CM; Zajc CU; Peters T; Schoeber MA; Kovacic B; Buri MC; Lobner E; Dushek O; Huppa JB; Obinger C; Putz EM; Holter W; Traxlmayr MW; Lehner M
    Nat Commun; 2020 Aug; 11(1):4166. PubMed ID: 32820173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response.
    Li X; Daniyan AF; Lopez AV; Purdon TJ; Brentjens RJ
    Leukemia; 2021 Feb; 35(2):506-521. PubMed ID: 32447345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
    Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
    Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Base-edited CAR T cells for combinational therapy against T cell malignancies.
    Georgiadis C; Rasaiyaah J; Gkazi SA; Preece R; Etuk A; Christi A; Qasim W
    Leukemia; 2021 Dec; 35(12):3466-3481. PubMed ID: 34035409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.
    Weimin S; Abula A; Qianghong D; Wenguang W
    Cancer Biol Ther; 2020 Jun; 21(6):570-580. PubMed ID: 32208880
    [No Abstract]   [Full Text] [Related]  

  • 16. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
    Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
    [No Abstract]   [Full Text] [Related]  

  • 17. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
    Moon EK; Wang LC; Dolfi DV; Wilson CB; Ranganathan R; Sun J; Kapoor V; Scholler J; Puré E; Milone MC; June CH; Riley JL; Wherry EJ; Albelda SM
    Clin Cancer Res; 2014 Aug; 20(16):4262-73. PubMed ID: 24919573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
    Tasian SK; Kenderian SS; Shen F; Ruella M; Shestova O; Kozlowski M; Li Y; Schrank-Hacker A; Morrissette JJD; Carroll M; June CH; Grupp SA; Gill S
    Blood; 2017 Apr; 129(17):2395-2407. PubMed ID: 28246194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel chimeric antigen receptor redirecting T-cell specificity towards CD26
    Zhou S; Li W; Xiao Y; Zhu X; Zhong Z; Li Q; Cheng F; Zou P; You Y; Zhu X
    Leukemia; 2021 Jan; 35(1):119-129. PubMed ID: 32317776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.